Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
N. Fazio
Observed name:
Fazio N
Institution:
European Institute of Oncology
Observed institution:
European Institute of Oncology
ORCID:
0000-0001-6869-0704
Observed ORCID:
0000-0001-6869-0704
OpenAlex ID:
A5121071004
Cetuximab rechallenge in molecularly selected metastatic colorectal cancer: the randomized CAVE-2 GOIM trial
2025
·
D. Ciardiello
, G. Martini
, et al.
·
Annals of Oncology
·
18
PDF
77P Predictive biomarkers for cetuximab-based rechallenge in metastatic colorectal cancer: A pooled analysis of CAVE and CAVE-2 studies
2026
·
D. Ciardiello
, G. Martini
, et al.
·
Annals of Oncology
165TiP Irinotecan plus cetuximab rechallenge versus trifluridine/tipiracil plus bevacizumab as third-line treatment in circulating tumor DNA–selected metastatic colorectal cancer (ROMANCE trial)
2026
·
G. Pellizzari
, M.G. Zampino
, et al.
·
Annals of Oncology
PDF
2RO Cetuximab in the continuum of care of molecularly selected metastatic colorectal cancer: The CAPRI-2 GOIM trial
2026
·
G. Martini
, S. Napolitano
, et al.
·
Annals of Oncology
PDF
HER-2 gene alterations as biomarker in patients with metastatic colorectal cancer treated with FOLFIRI + cetuximab: findings from the CAPRI-2 GOIM study
2026
·
D. Ciardiello
, L. Boscolo Bielo
, et al.
·
ESMO Gastrointestinal Oncology
PDF
Show more works
View as search
Works count:
6
Citation count:
18
H-index:
1
I10-index:
1
Year
Topic
Type